Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars (KELOID)
Primary Purpose
Keloid, Hypertrophic Scars
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Laser coagulation
Laser w/o coagulation
Sponsored by
About this trial
This is an interventional treatment trial for Keloid focused on measuring Keloid, Hypertrophic scars, Er-YAG Lasers
Eligibility Criteria
Inclusion Criteria:
- Given written informed consent
- Skin type I-IV
- Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type
- Willingness and ability to adhere study protocol
Exclusion Criteria
- History of adverse events related to ablative fractional laser therapy
- Ablative resurfacing within the last 6 months on the scar
- Oral retinoid, any immunosuppressive treatments in the last 6 months
- Pregnancy, lactation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Laser coagulation
Laser w/o coagulation
Arm Description
Er:YAG laser treatment with coagulation modality
Er:YAG laser treatment without coagulation modality
Outcomes
Primary Outcome Measures
Any reduction from baseline of scars volume as assessed by image analysis
Secondary Outcome Measures
Any reduction from baseline of scars volume as assessed by image analysis
Any improvement of scars as assessed by physician according to an ordinal 6-points scale
Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale
Erythema index as assessed by image analysis
Hypopigmentation as assessed by image analysis
Full Information
NCT ID
NCT02546076
First Posted
September 2, 2015
Last Updated
April 12, 2017
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT02546076
Brief Title
Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
Acronym
KELOID
Official Title
Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of patients
Study Start Date
May 2016 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Skin injuries due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars.
The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars.
The main hypothesis is that ablative fractional laser without heat/coagulation is equivalent to laser with heat/coagulation in terms of scars volume reduction, while the secondary hypothesis is that ablative fractional laser without heat/coagulation is superior in terms of post-operative erythema and hypopigmentation reduction.
Detailed Description
Background
Skin injuries, such as lacerations or abrasions, due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Multiple modalities for improving the clinical appearance of scars have been attempted with varying success, including corticosteroids, dermabrasion, surgical revision, chemical peeling, silicone gel application, pressure therapy, and radiation. Lasers such as the carbon dioxide (CO2), erbium: yttrium-aluminum-garnet (Er:YAG), and pulsed dye (PDL) lasers have all been used with differing success in the treatment of scars. The goal of all these treatments is to soften depressions and stimulate neocollagenesis in order to fill in the residual defects.
Ablative lasers used for skin resurfacing, such as the CO2 and Er:YAG laser, can reduce various scars, but significant adverse effects limit their use, and patient downtime can be extensive. Owing to these potential risks, nonablative lasers have been developed as a safe alternative to ablative laser resurfacing, and have been reported to be effective and safe for scars. However outcomes have remained unsatisfactory and require several treatments to achieve satisfactory efficacy.
Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars, and some authors have suggested that treatment with fractional lasers for various scars, such as postoperative, atrophic, and acne scars, has been demonstrated to safely improve the appearance of the scars. However, there is a lack of studies comparing coagulation modality of such lasers.
Objective
The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars.
Methods
This is a single center, investigator initiated, double blind, within-subject split-lesion design, equivalence randomized clinical study.
Consecutive patients, referring to Dermatology outpatient and fulfilling inclusion criteria, are included. Participants are then randomly assigned to get treatment with Er:YAG laser on half of scar section side by equally splitting the lesion area in two symmetric and uniform parts. One side will be treated with coagulation while the other one will be without. In case of multiple lesions per patient, only the largest and most uniform one is selected for the study purpose.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keloid, Hypertrophic Scars
Keywords
Keloid, Hypertrophic scars, Er-YAG Lasers
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Laser coagulation
Arm Type
Active Comparator
Arm Description
Er:YAG laser treatment with coagulation modality
Arm Title
Laser w/o coagulation
Arm Type
Active Comparator
Arm Description
Er:YAG laser treatment without coagulation modality
Intervention Type
Device
Intervention Name(s)
Laser coagulation
Intervention Description
The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
Intervention Type
Device
Intervention Name(s)
Laser w/o coagulation
Intervention Description
The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
Primary Outcome Measure Information:
Title
Any reduction from baseline of scars volume as assessed by image analysis
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Any reduction from baseline of scars volume as assessed by image analysis
Time Frame
4, 8, 12, 16, 24 weeks
Title
Any improvement of scars as assessed by physician according to an ordinal 6-points scale
Time Frame
4, 8, 12, 16, 24 weeks
Title
Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale
Time Frame
16, 24 weeks
Title
Erythema index as assessed by image analysis
Time Frame
4, 8, 12, 16, 24 weeks
Title
Hypopigmentation as assessed by image analysis
Time Frame
4, 8, 12, 16, 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Given written informed consent
Skin type I-IV
Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type
Willingness and ability to adhere study protocol
Exclusion Criteria
History of adverse events related to ablative fractional laser therapy
Ablative resurfacing within the last 6 months on the scar
Oral retinoid, any immunosuppressive treatments in the last 6 months
Pregnancy, lactation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maurice Adatto, MD
Organizational Affiliation
Dep. of Dermatology, Inselspital University Hospital, Bern (Switzerland)
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
We'll reach out to this number within 24 hrs